Overview
Ketamine and psilocybin are both classified as psychedelic or dissociative compounds that produce altered states of consciousness. Both have demonstrated rapid antidepressant effects in clinical trials, but they differ fundamentally in mechanism, legal status, treatment protocol, and accessibility.
Ketamine has been an FDA-approved anesthetic since 1970 and is legally prescribed off-label for depression nationwide. Psilocybin remains a Schedule I controlled substance at the federal level, though Oregon legalized supervised psilocybin services in 2023 and several cities have deprioritized enforcement.
Mechanism Comparison
| Aspect | Ketamine | Psilocybin |
|---|---|---|
| Primary receptor | NMDA glutamate receptor (antagonist) | 5-HT2A serotonin receptor (agonist) |
| Downstream effects | BDNF, mTOR, AMPA activation | Neuroplasticity, default mode network disruption |
| Subjective experience | Dissociation, floating, altered perception | Visual changes, emotional insight, ego dissolution |
| Duration of acute effects | 45 to 90 minutes | 4 to 6 hours |
| Neuroplasticity window | Hours to days | Days to weeks |
Ketamine primarily blocks NMDA receptors, leading to a glutamate surge and rapid synaptogenesis via the BDNF-mTOR pathway. For a detailed explanation of this cascade, see how ketamine works in the brain. Psilocybin (converted to psilocin) activates 5-HT2A serotonin receptors, disrupting default mode network activity and promoting neuroplasticity through distinct but partially overlapping molecular cascades.
Clinical Evidence
Ketamine has been studied in over 40 randomized controlled trials for depression, with meta-analyses confirming rapid antidepressant effects. The evidence base spans nearly three decades and includes thousands of patients.
Psilocybin has fewer but increasingly rigorous trials. The COMPASS Pathways Phase IIb trial (2022) demonstrated significant depression reduction with a single 25 mg dose. Davis et al. (2021) at Johns Hopkins found that two psilocybin sessions produced large, rapid decreases in depression scores, with 71 percent of participants showing greater than 50 percent reduction in symptoms at 4 weeks.
Treatment Protocol
| Factor | Ketamine | Psilocybin |
|---|---|---|
| Number of initial sessions | 6 over 2 to 3 weeks | 1 to 2 over 2 to 4 weeks |
| Session duration | 1 to 2 hours | 6 to 8 hours (including preparation) |
| Ongoing maintenance | Every 2 to 8 weeks | May not require regular dosing |
| Therapeutic support | Medical monitoring | Trained facilitator/therapist required |
| Duration of antidepressant effect | Days to weeks per session | Weeks to months per session |
A striking difference is treatment frequency. Ketamine typically requires ongoing maintenance sessions. Psilocybin trials suggest that one or two sessions can produce effects lasting months, though long-term durability data remains limited.
Accessibility and Legal Status
| Factor | Ketamine | Psilocybin |
|---|---|---|
| Legal status (US) | Schedule III, legal medical use | Schedule I (except Oregon, some cities) |
| FDA approval | Yes (as anesthetic); esketamine for TRD | Not yet (breakthrough therapy designation) |
| Provider availability | Thousands of clinics nationwide | Oregon licensed centers only (limited) |
| At-home options | Yes (oral/sublingual with telehealth) | No |
| Insurance coverage | Limited (esketamine sometimes covered) | None |
Safety Profile
Both substances are generally well-tolerated in clinical settings. Ketamine's acute effects include dissociation, nausea, and transient blood pressure elevation. Psilocybin's acute effects include anxiety, nausea, and challenging psychological experiences.
Ketamine carries a risk of tolerance, dependence, and bladder toxicity with chronic frequent use. Psilocybin has minimal addiction potential and no known organ toxicity, but carries risks of psychological distress during sessions and is contraindicated in patients with psychotic disorders.
References
- Goodwin et al. — COMPASS Pathways Psilocybin Trial — Single-dose psilocybin for treatment-resistant depression
- Davis et al. — Johns Hopkins Psilocybin Trial — Effects of psilocybin-assisted therapy on major depressive disorder
- Kishimoto et al. — Ketamine Meta-Analysis — Single-dose ketamine meta-analysis
- NIMH — Psychedelic Research — NIMH depression research information
Verdict
Ketamine is currently the only legal and widely accessible psychedelic-adjacent treatment for depression, with robust clinical evidence and established infrastructure. Psilocybin shows extraordinary promise in clinical trials, with potentially longer-lasting effects from fewer sessions, but remains available only in limited settings. For patients seeking treatment now, ketamine is the practical choice. Psilocybin may offer advantages when broader access becomes available.
Share